Clinical Application Research on Differentiating Benign and Malignant Pulmonary Nodules Based on Multi-omics Detection Technology
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Changes in peripheral blood immune indicators, differences in radiomics and clinicopathological characteristics
研究概览
简要总结
Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer
详细描述
Research design: It is planned to collect pulmonary nodules confirmed by preoperative CT during the period from January 2021 to June 2020 The peripheral blood and clinical information of 100 patients who underwent surgical operations were classified according to the pathological diagnosis of the patients It is the malignant pulmonary nodule group and the benign pulmonary nodule group. Through single-cell sequencing, flow cytometry analysis and radiomics The purpose of identifying the benign and malignant nature of pulmonary nodules is: ① To predict the benign and malignant nature of pulmonary nodules before surgery; ② Explore evil the differences in the immune microenvironment between patients with sexual and benign pulmonary nodules, and the search for specific markers with clinical value Object ③ Compare the diagnostic sensitivity of the new prediction method with that of traditional tumor markers and explore its role as a predictor The potential for measuring the benign and malignant nature of pulmonary nodules
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patient underwent a ct examination
- •Patient was confirmed to have pulmonary nodules
- •Patient has been determined to undergo surgical treatment
- •There are clear pathological results
- •The clinicopathological data are complete
排除标准
- •Patient has no ct examination results
- •Refuse surgical treatment
- •Patient has no clear pathological diagnosis
- •Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
- •Patients with tumor emergencies that require immediate treatment.
- •Poor vascular conditions.
- •Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
- •Patients with hematogenic infectious diseases, such as HBV.
- •Patients with psychiatric disorders or severe mental illnesses.
- •Patients who have difficulty communicating or are unable to be followed up for a long time
结局指标
主要结局
Changes in peripheral blood immune indicators, differences in radiomics and clinicopathological characteristics
时间窗: Before surgery for patients with pulmonary nodules
Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules.
时间窗: Before surgery for patients with pulmonary nodules
Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules. The flow cytometry antibodies used to label activated T cells in this study include CD19, CD3, CD4, CD8. CD25, CD39, CD137,Foxp3, IFN γ, etc.
次要结局
未报告次要终点
研究者
Zhao Jun
Thoracic Surgery
The First Affiliated Hospital of Soochow University